Other News

Clinical Data from Reprieve Cardiovascular’s Successful First-in-Human Therapy for Acute Heart Failure Presented

Personalized Volume Management System : 2nd generation automated fluid management technology MILFORD, Mass., Dec. 13, 2019 /PRNewswire/ — Reprieve Cardiovascular®, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced the results of the first-in-human clinical trial with the company’s second generation device, […]

FDA Clears Two Siemens Healthineers CT Systems Dedicated for Radiation Therapy Planning

• SOMATOM go.Sim and SOMATOM go.Open Pro help customers meet challenges in RT treatment planning The U.S. Food and Drug Administration (FDA) has cleared the SOMATOM go.Sim and SOMATOM go.Open Pro – two computed tomography (CT) systems from Siemens Healthineers that are dedicated for radiation therapy (RT) planning. The 64-slice SOMATOM […]

Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

WINNIPEG, Dec. 12, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, notably tirofiban (an IV GP IIb/IIIa inhibitor) and cangrelor (an […]

CORREVIO PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Correvio Pharma Corp. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Correvio Pharma Corp. (NASDAQ: CORV) securities between October 23, […]

scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX® and Highlights Corporate Objectives

Successful completion of human factors program ahead of FUROSCIX NDA resubmission BURLINGTON, Mass.–(BUSINESS WIRE)–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a progress update on […]

Elucid Bioimaging Relocates Headquarters to Downtown Boston

BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. is pleased to announce it has relocated its headquarters to 2 Park Plaza in downtown Boston. “This move helps facilitate Elucid’s ongoing expansion and provides increased proximity to research institutes, provider partners, and technology talent,” said CEO Blake Richards. Elucid is also pleased to announce the […]

Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group. This feasibility evaluation will involve the development of oral formulations using Matinas’ lipid nano-crystal (LNC) platform delivery technology, which […]

Enrollment Complete for VALUE, the Prospective EU VasQ™ External Support Post-Market Study

TEL AVIV, Israel, Dec. 11, 2019 /PRNewswire/ — Laminate Medical Technologies (Laminate) has announced the completion enrollment of the VALUE study for the VasQ™ External Support. The post-market study enrolled 80 patients (50 upper arm and 30 forearm fistulas) for sites across Germany, France, Spain and the UK and will be followed for one year. The study is the […]

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”). The award was approved by the Company’s Compensation Committee, which is comprised of independent directors, on […]